Chester County News and Community Website
Neuronetics, Inc. (NASDAQ: STIM), headquartered in Malvern, PA, is a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders.
MALVERN, PA — Neuronetics, Inc. (NASDAQ: STIM) will share updates on its growing portfolio of noninvasive mental health treatments during a fireside chat at the Piper Sandler 37th Annual Healthcare …
Neuronetics to Spotlight Expanding Mental Health Therapies at Major Industry Forum Read More MALVERN, PA — Neuronetics, Inc. (NASDAQ: STIM) announced a significant coverage expansion for its NeuroStar transcranial magnetic stimulation (TMS) therapy, as TriWest — the regional administrator for TRICARE — updated …
TRICARE Expands TMS Coverage for Teens as Neuronetics Gains Major Policy Win Read More MALVERN, PA — Neuronetics, Inc. (NASDAQ: STIM) reported significant third-quarter gains, driven by the successful integration of Greenbrook TMS and expanding adoption of its NeuroStar Advanced Therapy System. The company …
Neuronetics Sees Strong Growth and Leadership Shift as Integration Gains Momentum Read More MALVERN, PA — Neuronetics, Inc. (NASDAQ: STIM) recently announced the granting of restricted stock units (RSUs) to twelve new employees as inducement awards under its 2020 Inducement Incentive Plan.
Neuronetics Awards Equity Grants to 12 New Employees as Hiring Momentum Builds Read More MALVERN, PA — Neuronetics, Inc. (NASDAQ: STIM) has entered an exclusive three-year agreement with Elite DNA Behavioral Health to become the sole provider of transcranial magnetic stimulation (TMS) devices across …
Neuronetics Expands TMS Reach Through Exclusive Partnership With Elite DNA Read More MALVERN, PA — Neuronetics, Inc. (NASDAQ: STIM) announced Wednesday that New York State Medicaid will begin covering transcranial magnetic stimulation (TMS) for adults with major depressive disorder (MDD), a move …
Neuronetics Gains Breakthrough as New York Medicaid Expands Coverage for TMS Depression Therapy Read More MALVERN, PA — Neuronetics, Inc. (NASDAQ: STIM) has granted equity awards to six recently hired employees as inducements to join the company. The grants, consisting of restricted stock units (RSUs), …
Neuronetics Issues Inducement Equity Awards to New Hires Read More MALVERN, PA — Neuronetics, Inc. (NASDAQ: STIM) delivered a solid second quarter, posting $38.1 million in total revenue—an 18% increase on an adjusted pro forma basis—as the company continues to benefit …
Neuronetics Posts Strong Q2 Revenue Growth, Secures $10M in New Funding as Greenbrook Integration Advances Read More MALVERN, PA — Neuronetics, Inc. (NASDAQ: STIM) announced new real-world data demonstrating that its NeuroStar transcranial magnetic stimulation (TMS) therapy delivers meaningful improvement in depression symptoms among adolescents and young adults. …
Neuronetics Study Shows Strong Antidepressant Results for Teens and Young Adults Using NeuroStar TMS Read More MALVERN, PA — Neuronetics, Inc. (NASDAQ: STIM) announced that Steven Pfanstiel will join the company as Chief Financial Officer, effective July 15, 2025. He succeeds Steve Furlong, who will retire …
Neuronetics Appoints New CFO as Company Targets Growth and Profitability Milestones Read More